Less frequent natalizumab (Tysabri)
Extending infusions of natalizumab (Tysabri) to every eight weeks was just as effective as every four weeks according to a study presented at the American Academy of Neurology (AAN) meeting.
Newswise
Natalizumab (Tysabri) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 19, 2015 Category: Neurology Source Type: news
Cyclical suicidal ideation following natalizumab infusion for multiple sclerosis - Nagesh O, Bastiampillai T, Fisher L, Mohan T.
[Abstract unavailable]
Language: en... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - February 20, 2015 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news
Side effects of Gilenya and Tysabri
Review article includes varicella-zoster infections associated with fingolimod (Gilenya) and antiNMDA antibodies resulting from stopping treatment with natalizumab (Tysabri) .
MedPage Today
Fingolimod (Gilenya) - A to Z of MS
Natalizumab (Tysabri) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - December 18, 2014 Category: Neurology Source Type: news
Hot Topics: Best Use of Tysabri in MS
(MedPage Today) -- Who should take the potent but risky drug? (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - December 16, 2014 Category: Neurology Source Type: news
Long-term safety of natalizumab for treating multiple sclerosis
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - October 16, 2014 Category: Consumer Health News Source Type: news
Smoking Ups Natalizumab Neutralizing Antibodies in MSSmoking Ups Natalizumab Neutralizing Antibodies in MS
Smoking Ups Natalizumab Neutralizing Antibodies in MS Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 3, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
New Test to Identify PML Risk With Natalizumab in MSNew Test to Identify PML Risk With Natalizumab in MS
The test, which detects low levels of L-selectin in the blood, is said to have a sensitivity of about 90%, and even higher rates when combined with JC virus antibody status. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 29, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
PML in MS Patients Making Natalizumab-to-Fingolimod SwitchPML in MS Patients Making Natalizumab-to-Fingolimod Switch
A new report describes several cases of PML seen in patients with MS receiving fingolimod, all but 1 of which were treated previously with natalizumab. Authors say this patient had neuromyelitis optica, not MS, with atypical features. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 25, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
MS medications and pregnancy
Summary of some recent studies that have looked at pregnancy outcomes on women using various medications for MS (Betaferon, Tysabri and Gilenya), plus one study where the fathers were on treatment.
MS Research Australia
Pregnancy - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - August 4, 2014 Category: Neurology Source Type: news
The effects of stopping natalizumab (Tysabri)
An Italian study (n=130) found that people who stopped taking natalizumab after 24 doses saw an increase in disease activity.
MSIF
Natalizumab (Tysabri) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - July 8, 2014 Category: Neurology Source Type: news
Fingolimod (Gilenya) eligibility extended by NHS England
Fingolimod can now be prescribed on the NHS in England for people who continue to have relapses despite taking beta interferon or glatiramer acetate and for people taking natalizumab who are at high risk of developing progressive multifocal leukoencephalopathy (PML). (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - July 1, 2014 Category: Neurology Source Type: news
Relapses increase post Tysabri
Another study finds that stopping natalizumab (Tysabri) or switching to another disease modifying drug led to an increased risk of relapses.
2 Minute Medicine
Natalizumab (Tysabri) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - June 30, 2014 Category: Neurology Source Type: news
Natalizumab Continued Past 24 Months Safely in MSNatalizumab Continued Past 24 Months Safely in MS
Results from the TY-STOP observational study show patients with MS safely continued natalizumab past 24 months and had less disease activity vs going to a different drug or stopping all together. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
To Stay, or Not to Stay, on Natalizumab in MSTo Stay, or Not to Stay, on Natalizumab in MS
As PML risk is greatest after 2 years of taking natalizumab, patients may consider switching to another drug, but a new study suggests that those who do are at increased risk for disability progression. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 2, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Shorter Washout Better for Natalizumab-to-Fingolimod Switch Shorter Washout Better for Natalizumab-to-Fingolimod Switch
A new study further confirms that upon switching from natalizumab to fingolimod in patients with multiple sclerosis, the washout period should be less than 3 months. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 26, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
